Carisma Therapeutics (CARM) announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte, or CAR-M, therapy for hepatocellular carcinoma, or HCC, ...
Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ...
MB-109 is Mustang's regimen that combines MB-101, a chimeric antigen receptor (CAR)-T-cell therapy targeting interleukin 13 ...
These findings suggest that KIR2DS2-positive (KIR2DS2+) natural killer (NK) cells could be an attractive therapeutic target ...
The in vivo cell therapy seed Carisma Therapeutics planted with Moderna in 2022 is starting to sprout. | The in vivo cell ...
today announced positive pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor macrophage and monocyte (together, "CAR-M") therapy for hepatocellular carcinoma ("HCC"), developed in ...
To date, the Food and Drug Administration (FDA) has approved six chimeric antigen receptor (CAR) T cell therapy products targeting CD19 and BCMA for B-cell lymphomas, leukemias and multiple myeloma, ...
The international Phase 1 study, called CARLYSE, is the first in the UK to assess the potential of CAR-T (Chimeric Antigen ...
News Medical on MSN3d
Moderate expression of CD39 in GPC3-CAR-T cells shows high efficacy against hepatocellular carcinomaIn the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a study in Frontiers of Medicine has identified a pivotal role for CD39 ...
Carisma Therapeutics (CARM) announced the upcoming presentation of new pre-clinical data on its anti-GPC3 in vivo chimeric antigen receptor ...
ALLO-316, a CD70-targeting CAR T-cell therapy, has demonstrated activity in patients with previously treated, advanced ccRCC.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback